- Home
- BCML vs PBYI Comparison
BCML vs PBYI Comparison
Compare BCML & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCML | PBYI |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.3M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCML | PBYI |
|---|---|---|
| Price | $32.88 | $5.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $32.00 | $7.00 |
| AVG Volume (30 Days) | 18.1K | ★ 402.3K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 2.10 | 0.74 |
| Revenue | $94,896,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | $15.65 | ★ $7.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.22 | $2.58 |
| 52 Week High | $32.98 | $6.12 |
Technical Indicators
Market Signals| Indicator | BCML | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 70.26 | 64.64 |
| Support Level | $27.94 | $4.84 |
| Resistance Level | $32.98 | $5.11 |
| Average True Range (ATR) | 0.92 | 0.20 |
| MACD | 0.32 | 0.09 |
| Stochastic Oscillator | 83.73 | 89.20 |
Price Performance
Historical ComparisonAbout BCML BayCom Corp
BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.